tradingkey.logo

Check Cap Ltd

CHEK

0.688USD

+0.011+1.59%
Horário de mercado ETCotações atrasadas em 15 min
4.03MValor de mercado
PerdaP/L TTM

Check Cap Ltd

0.688

+0.011+1.59%
Mais detalhes de Check Cap Ltd Empresa
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Informações da empresa
Código da empresaCHEK
Nome da EmpresaCheck Cap Ltd
Data de listagemFeb 19, 2015
CEOMr. Alex Ovadia
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 19
Endereço29 Abba Hushi Ave.
Cidade
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal3009000
Telefone97248303401
Sitehttps://check-cap.com/
Código da empresaCHEK
Data de listagemFeb 19, 2015
CEOMr. Alex Ovadia
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Dr. Hanit Brenner-lavie
Dr. Hanit Brenner-lavie
Vice President - Clinical Affairs
Vice President - Clinical Affairs
--
--
Mr. Dan Hilerowitz
Mr. Dan Hilerowitz
Chief Financial Officer
Chief Financial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
EquityLine Alternate Assets GP Inc
13.04%
Symetryx Corp
5.79%
J.P. Morgan Securities LLC
0.60%
Citadel Advisors LLC
0.36%
BNP Paribas Securities Corp. North America
0.34%
Other
79.87%
Investidores
Investidores
Proporção
EquityLine Alternate Assets GP Inc
13.04%
Symetryx Corp
5.79%
J.P. Morgan Securities LLC
0.60%
Citadel Advisors LLC
0.36%
BNP Paribas Securities Corp. North America
0.34%
Other
79.87%
Tipos de investidores
Investidores
Proporção
Corporation
18.83%
Research Firm
1.02%
Hedge Fund
0.55%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.08%
Other
79.32%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
39
1.57M
26.85%
+1.07M
2025Q1
42
1.57M
26.85%
+1.00M
2024Q4
44
1.61M
27.59%
+1.15M
2024Q3
45
1.48M
25.29%
+968.05K
2024Q2
48
1.48M
25.22%
+958.50K
2024Q1
57
722.40K
12.35%
+185.59K
2023Q4
59
777.23K
13.29%
+83.98K
2023Q3
61
699.06K
11.95%
+309.38K
2023Q2
62
22.37K
0.38%
-595.96K
2023Q1
68
336.11K
6.40%
-190.75K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
EquityLine Alternate Assets GP Inc
762.72K
13.04%
+762.72K
--
Apr 05, 2024
Symetryx Corp
338.63K
5.79%
+37.76K
+12.55%
Nov 27, 2023
J.P. Morgan Securities LLC
35.36K
0.6%
+33.86K
+2257.07%
Mar 31, 2025
Citadel Advisors LLC
20.85K
0.36%
-1.68K
-7.46%
Mar 31, 2025
BNP Paribas Securities Corp. North America
19.84K
0.34%
+6.20K
+45.46%
Mar 31, 2025
Two Sigma Investments, LP
11.48K
0.2%
+11.48K
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.15%
--
--
Jan 31, 2025
Morgan Stanley & Co. LLC
3.90K
0.07%
-26.90K
-87.33%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.93K
0.05%
--
--
May 31, 2025
Shpigelman (Boaz)
1.23K
0.02%
+18.00
+1.49%
Apr 01, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Data
Tipo
Proporção
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
KeyAI